CJC-1295

Overview

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates sustained growth hormone secretion. The no-DAC (Drug Affinity Complex) version provides pulsatile GH release that more closely mimics natural physiology.

Mechanism of Action

CJC-1295 binds to the GHRH receptor on pituitary somatotroph cells, stimulating the synthesis and secretion of growth hormone. The modified amino acid sequence provides resistance to enzymatic degradation, extending its biological half-life.

Research Summary

Clinical trials have shown CJC-1295 increases GH and IGF-1 levels by 200–1000% without significantly altering other pituitary hormones. It is commonly studied in combination with GHRPs like ipamorelin for synergistic effects.

Dosing Information

Reported Side Effects

• Flushing
• Headache
• Dizziness
• Injection site reactions
• Water retention

Research References

• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295 (2006)
• Modified GRF (1-29) after subcutaneous administration in healthy subjects (2010)
• Growth hormone-releasing hormone analogs: chemistry and pharmacology (2012)